Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBM Psyence Biomedical	$5.50 +5.5%	$4.88	$2.93 ▼ $701.82	$3.13M	0.22	67,820 shs	15,513 shs
SQZB SQZ Biotechnologies	$0.03	$0.03	$0.02 ▼ $0.10	N/A	1.37	359 shs	1 shs
SXTP 60 Degrees Pharmaceuticals	$1.55 -5.8%	$2.37	$1.41 ▼ $35.99	$2.25M	2.78	1.19 million shs	852,827 shs
UBX UNITY Biotechnology	$0.18 -40.4%	$0.64	$0.20 ▼ $3.10	$3.08M	0.92	279,055 shs	3.73 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBM Psyence Biomedical	-0.57%	+6.33%	+19.50%	+49.21%	-98.01%
SQZB SQZ Biotechnologies	0.00%	0.00%	0.00%	0.00%	-24.32%
SXTP 60 Degrees Pharmaceuticals	-6.29%	-33.33%	-24.07%	-48.10%	+40.17%
UBX UNITY Biotechnology	0.00%	0.00%	-77.93%	-81.55%	-88.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PBM Psyence Biomedical	0.9879 of 5 stars	0.0	3.0	0.0	0.0	2.7	1.7	0.6
SQZB SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.6887 of 5 stars	3.3	3.0	0.0	0.0	2.4	2.5	0.6
UBX UNITY Biotechnology	4.6533 of 5 stars	3.3	5.0	0.0	4.7	4.4	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PBM Psyence Biomedical	0.00	N/A	N/A	N/A
SQZB SQZ Biotechnologies	0.00	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	353.07% Upside
UBX UNITY Biotechnology	2.50	Moderate Buy	$3.75	1,994.97% Upside

Current Analyst Ratings Breakdown

Latest SQZB, SXTP, UBX, and PBM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/16/2025	UBX UNITY Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
5/10/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/23/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PBM Psyence Biomedical	N/A	N/A	$1.84 per share	2.98	$11.83 per share	N/A
SQZB SQZ Biotechnologies	$21.48M	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	$665.45K	3.42	N/A	N/A	($6.38) per share	-0.24
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	$0.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PBM Psyence Biomedical	$1.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SQZB SQZ Biotechnologies	-$79.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-1,947.30%	N/A	-174.90%	8/13/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	7/22/2025 (Estimated)

Latest SQZB, SXTP, UBX, and PBM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SXTP 60 Degrees Pharmaceuticals	-$1.24	N/A	N/A	N/A	$0.32 million	N/A
8/5/2025	Q2 2025	UBX UNITY Biotechnology	-$0.30	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million
4/22/2025	Q1 2025	UBX UNITY Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A
SQZB SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PBM Psyence Biomedical	N/A	11.04	11.04
SQZB SQZ Biotechnologies	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PBM Psyence Biomedical	77.44%
SQZB SQZ Biotechnologies	12.41%
SXTP 60 Degrees Pharmaceuticals	7.96%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
PBM Psyence Biomedical	3.60%
SQZB SQZ Biotechnologies	16.00%
SXTP 60 Degrees Pharmaceuticals	10.27%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PBM Psyence Biomedical	N/A	570,000	548,000	N/A
SQZB SQZ Biotechnologies	120	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

SQZB, SXTP, UBX, and PBM Headlines

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice

June 30, 2025 | finance.yahoo.com

Unity Biotechnology stock plunges after Nasdaq delisting notice

June 30, 2025 | za.investing.com

Unity Biotechnology Inc News (UBX) - Investing.com

June 26, 2025 | investing.com

UBX Unity Biotechnology, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 6, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.comF

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.comO

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.comT

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZB, SXTP, UBX, and PBM Company Descriptions

Psyence Biomedical NASDAQ:PBM

$5.50 +0.29 (+5.47%)

As of 01:07 PM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

SQZ Biotechnologies OTCMKTS:SQZB

$0.03 0.00 (0.00%)

As of 07/15/2025

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.54 -0.10 (-5.79%)

As of 01:08 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

UNITY Biotechnology NASDAQ:UBX

$0.18 -0.12 (-40.43%)

Closing price 07/8/2025

Extended Trading

$0.18 0.00 (0.00%)

As of 07/8/2025 07:59 PM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time